CureVac share: record sales and jump in profits – that’s what’s behind it!

On March 20, 2025, the CureVac share was one of the best performers of the day on the German stock market. Loud finance.net The share price increased by 0.9 percent and reached a value of EUR 2.79 in the Tradegate meeting. During the trading day, the price reached a daily high of EUR 2.87 after the share opened at EUR 2.75. A total of 102,700 shares were traded.

The current price level remains significantly below the 52-week high of EUR 4.98, which was marked on January 7, 2025. To reach this high, an increase of 78.42 percent would be required. In comparison, the 52-week low is EUR 2.06, reached on April 26, 2024, which represents a loss of 26.09 percent should the price fall back to this level. The expected dividend for 2024 is EUR 0.000. Analysts have set an average price target of $3.90.

Positive business results from CureVac

The business results of the Tübingen vaccine developer provide further optimism. How boerse-express.com reported, CureVac saw revenue increase by more than 2,900 percent to $542.57 million. Earnings per share were $1.66, a significant increase compared to the same period last year, which reported a loss of $0.24 per share.

On Tuesday, the CureVac share showed changeable price movements in Tradegate trading, with a starting price of EUR 2.70 and a daily high of EUR 2.78, before the price fell by 1.2 percent to EUR 2.70 in the afternoon. In total trading volume, 113,003 shares were traded. The current price is about 80 percent below the 52-week high, but has recovered about 30 percent from the 52-week low. CureVac has also increased its strategic focus on research. The next release of financial results for the fourth quarter of 2024 is on April 23, 2025 and analysts are forecasting full-year 2024 earnings of EUR 0.793 per share.